Pelacarsen Misses Primary Endpoint in Lp(a)HORIZON Trial

Published September 9, 2026, after Novartis reported topline results from the Lp(a)HORIZON trial.

Novartis said September 4 that pelacarsen, an investigational drug designed to lower lipoprotein(a), did not meet the primary endpoint in its Phase 3 Lp(a)HORIZON cardiovascular outcomes trial. The company reported lower Lp(a) levels with pelacarsen, but the trial did not meet its primary endpoint across the overall study population.

The announcement is important because Lp(a)HORIZON was the first pivotal Phase 3 trial built to test whether reducing Lp(a) could lower cardiovascular risk in people who already had cardiovascular disease. It also leaves several central questions unanswered because Novartis released no event rates, hazard ratios, confidence intervals, or numerical Lp(a) reductions.

What Lp(a)HORIZON tested

Lp(a)HORIZON (NCT04023552) was a randomized, placebo-controlled, double-blind trial involving 8,323 participants with established cardiovascular disease and elevated Lp(a). The overall population had Lp(a) of at least 70 mg/dL, and the study also specified a subgroup at or above 90 mg/dL. Those numbers were trial eligibility and analysis boundaries, not new clinical cutoffs for interpreting an Lp(a) result.

The primary endpoint combined four outcomes: cardiovascular death, non-fatal heart attack, non-fatal stroke, and urgent coronary revascularization requiring hospitalization. Participants received guideline-directed care, including lipid-lowering and blood-pressure treatment, while the trial compared pelacarsen with placebo.

Pelacarsen is an antisense oligonucleotide designed to inhibit production of apolipoprotein(a), the protein that distinguishes Lp(a) from standard LDL particles. Ionis discovered the drug and licensed it to Novartis for development and commercialization.

What the topline result does not show

The sponsor releases say pelacarsen lowered Lp(a), but they do not quantify the reduction. They also do not show whether event rates differed within the group whose baseline Lp(a) was at least 90 mg/dL or within any other subgroup. Novartis says the full results will be presented at a future medical congress.

Until those data are public, the narrow conclusion is that the trial did not meet its composite cardiovascular primary endpoint across the overall study population. The release does not establish why. It is sponsor-reported topline information, not a peer-reviewed results paper.

What this means for Lp(a) as a risk marker

A negative drug trial is not the same as a negative biomarker study. Lp(a)HORIZON tested whether one intervention improved outcomes in a secondary-prevention population. It did not test whether Lp(a) is associated with cardiovascular risk.

The 2026 ACC/AHA dyslipidemia guideline describes Lp(a) as a largely inherited and relatively stable risk marker and recommends measuring it at least once in adulthood. This trial does not amend that guideline. It does, however, challenge the simple assumption that lowering the biomarker with any drug will automatically lower clinical-event risk.

LabTestSuperstore's Lp(a) test page explains what the blood test measures and how results are reported. A May 2026 Hot Take on VESALIUS-CV covers the separate observational evidence linking Lp(a) with coronary events. The new pelacarsen result addresses a different question: whether one Lp(a)-lowering therapy changes outcomes.

What to watch next

The full Lp(a)HORIZON presentation should show the absolute event rates, treatment effect estimate, confidence interval, achieved Lp(a) reduction, subgroup analyses, and fuller safety data. Those details will determine whether the result was uniformly neutral or whether any narrower signal deserves further study.

Other investigational Lp(a)-lowering programs will need their own outcomes data. A biomarker change alone cannot establish that a treatment prevents heart attacks, strokes, or cardiovascular deaths.

This article is editorial commentary and is not medical advice. It has not been reviewed by a physician and should not be used to make individual decisions about cardiovascular diagnosis, medication, treatment, or testing.